Skip to main content
Top
Published in: International Journal of Hematology 5/2020

01-11-2020 | Acute Lymphoblastic Leukemia | Original Article

Functional analysis of a novel fusion protein PAX5-KIDINS220 identified in a pediatric Ph-like ALL patient

Authors: Takuyo Kanayama, Toshihiko Imamura, Azusa Mayumi, Emi Soma, Kenichi Sakamoto, Fumihiko Hayakawa, Akihiko Tanizawa, Nobutaka Kiyokawa, Hajime Hosoi

Published in: International Journal of Hematology | Issue 5/2020

Login to get access

Abstract

PAX5-KIDINS220 (PAX5-K220) is a novel chimeric fusion gene identified in a pediatric Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) patient, but the function of the encoded fusion protein has not yet been analyzed. Here, we report the functional analysis of PAX5-K220 in vitro. We successfully generated PAX5-K220 expressing cells and demonstrate that PAX5-K220 is a nuclear protein. Luciferase reporter assay reveals that PAX5-K220 inhibits wild-type PAX5 transcriptional activity in a dominant-negative fashion like other PAX5-related fusion proteins, and may contribute to lymphocyte differentiation block. However, although identified in Ph-like ALL, PAX5-K220 does not induce IL-3-independent proliferation when transduced in the IL-3-dependent Ba/F3 murine leukemia cells, but rather attenuates growth. These results reveal that PAX5-K220 certainly shares the character with other PAX5-related fusion proteins rather than other fusion proteins with tyrosine kinase activity identified in Ph-like ALL, and did not contribute to proliferation activity. Precise functional analysis of each differently partnered PAX5 fusion protein is warranted in the future for better understanding of PAX5-related translocations and their effects.
Literature
1.
go back to reference Coyaud E, Struski S, Prade N, Familiades J, Eichner R, Quelen C, et al. Wide diversity of PAX5 alterations in B-ALL: a groupe francophone de cytogenetique hematologique study. Blood. 2010;115(15):3089–97.CrossRef Coyaud E, Struski S, Prade N, Familiades J, Eichner R, Quelen C, et al. Wide diversity of PAX5 alterations in B-ALL: a groupe francophone de cytogenetique hematologique study. Blood. 2010;115(15):3089–97.CrossRef
2.
go back to reference Nebral K, Denk D, Attarbaschi A, Konig M, Mann G, Haas OA, et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia. 2009;23(1):134–43.CrossRef Nebral K, Denk D, Attarbaschi A, Konig M, Mann G, Haas OA, et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia. 2009;23(1):134–43.CrossRef
3.
go back to reference Bousquet M, Broccardo C, Quelen C, Meggetto F, Kuhlein E, Delsol G, et al. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5. Blood. 2007;109(8):3417–23.CrossRef Bousquet M, Broccardo C, Quelen C, Meggetto F, Kuhlein E, Delsol G, et al. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5. Blood. 2007;109(8):3417–23.CrossRef
4.
go back to reference Fazio G, Palmi C, Rolink A, Biondi A, Cazzaniga G. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells. Cancer Res. 2008;68(1):181–9.CrossRef Fazio G, Palmi C, Rolink A, Biondi A, Cazzaniga G. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells. Cancer Res. 2008;68(1):181–9.CrossRef
5.
go back to reference Kawamata N, Pennella MA, Woo JL, Berk AJ, Koeffler HP. Dominant-negative mechanism of leukemogenic PAX5 fusions. Oncogene. 2012;31(8):966–77.CrossRef Kawamata N, Pennella MA, Woo JL, Berk AJ, Koeffler HP. Dominant-negative mechanism of leukemogenic PAX5 fusions. Oncogene. 2012;31(8):966–77.CrossRef
6.
go back to reference Kurahashi S, Hayakawa F, Miyata Y, Yasuda T, Minami Y, Tsuzuki S, et al. PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML. Oncogene. 2011;30(15):1822–30.CrossRef Kurahashi S, Hayakawa F, Miyata Y, Yasuda T, Minami Y, Tsuzuki S, et al. PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML. Oncogene. 2011;30(15):1822–30.CrossRef
7.
go back to reference Schinnerl D, Fortschegger K, Kauer M, Marchante JR, Kofler R, Den Boer ML, et al. The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia. Blood. 2015;125(8):1282–91.CrossRef Schinnerl D, Fortschegger K, Kauer M, Marchante JR, Kofler R, Den Boer ML, et al. The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia. Blood. 2015;125(8):1282–91.CrossRef
8.
go back to reference Sakamoto K, Imamura T, Kanayama T, Yano M, Asai D, Deguchi T, et al. Ph-like acute lymphoblastic leukemia with a novel PAX5-KIDINS220 fusion transcript. Genes Chromosomes Cancer. 2017;56(4):278–84.CrossRef Sakamoto K, Imamura T, Kanayama T, Yano M, Asai D, Deguchi T, et al. Ph-like acute lymphoblastic leukemia with a novel PAX5-KIDINS220 fusion transcript. Genes Chromosomes Cancer. 2017;56(4):278–84.CrossRef
9.
go back to reference Iglesias T, Cabrera-Poch N, Mitchell MP, Naven TJ, Rozengurt E, Schiavo G. Identification and cloning of Kidins220, a novel neuronal substrate of protein kinase D. J Biol Chem. 2000;275(51):40048–56.CrossRef Iglesias T, Cabrera-Poch N, Mitchell MP, Naven TJ, Rozengurt E, Schiavo G. Identification and cloning of Kidins220, a novel neuronal substrate of protein kinase D. J Biol Chem. 2000;275(51):40048–56.CrossRef
10.
go back to reference Arevalo JC, Yano H, Teng KK, Chao MV. A unique pathway for sustained neurotrophin signaling through an ankyrin-rich membrane-spanning protein. EMBO J. 2004;23(12):2358–68.CrossRef Arevalo JC, Yano H, Teng KK, Chao MV. A unique pathway for sustained neurotrophin signaling through an ankyrin-rich membrane-spanning protein. EMBO J. 2004;23(12):2358–68.CrossRef
11.
go back to reference McNiece IK, Bradley TR, Kriegler AB, Hodgson GS. A growth factor produced by WEHI-3 cells for murine high proliferative potential GM-progenitor colony forming cells. Cell Biol Int Rep. 1982;6(3):243–51.CrossRef McNiece IK, Bradley TR, Kriegler AB, Hodgson GS. A growth factor produced by WEHI-3 cells for murine high proliferative potential GM-progenitor colony forming cells. Cell Biol Int Rep. 1982;6(3):243–51.CrossRef
12.
go back to reference Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 2000;7(12):1063–6.CrossRef Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 2000;7(12):1063–6.CrossRef
13.
go back to reference Fujiki A, Imamura T, Sakamoto K, Kawashima S, Yoshida H, Hirashima Y, et al. All-trans retinoic acid combined with 5-Aza-2’-deoxycytidine induces C/EBPalpha expression and growth inhibition in MLL-AF9-positive leukemic cells. Biochem Biophys Res Commun. 2012;428(2):216–23.CrossRef Fujiki A, Imamura T, Sakamoto K, Kawashima S, Yoshida H, Hirashima Y, et al. All-trans retinoic acid combined with 5-Aza-2’-deoxycytidine induces C/EBPalpha expression and growth inhibition in MLL-AF9-positive leukemic cells. Biochem Biophys Res Commun. 2012;428(2):216–23.CrossRef
14.
go back to reference Yoshida H, Imamura T, Fujiki A, Hirashima Y, Miyachi M, Inukai T, et al. Post-transcriptional modulation of C/EBPalpha prompts monocytic differentiation and apoptosis in acute myelomonocytic leukaemia cells. Leuk Res. 2012;36(6):735–41.CrossRef Yoshida H, Imamura T, Fujiki A, Hirashima Y, Miyachi M, Inukai T, et al. Post-transcriptional modulation of C/EBPalpha prompts monocytic differentiation and apoptosis in acute myelomonocytic leukaemia cells. Leuk Res. 2012;36(6):735–41.CrossRef
15.
go back to reference Tomii T, Imamura T, Yano M, Sakamoto K, Kato I, Tanaka K, et al. Leukemic cell expressing a novel kinase fusion protein NCOR1-LYN exhibits high sensitivity to Dasatinib and Rapamycin. Blood. 2018;132(Supplement 1):1557–1557.CrossRef Tomii T, Imamura T, Yano M, Sakamoto K, Kato I, Tanaka K, et al. Leukemic cell expressing a novel kinase fusion protein NCOR1-LYN exhibits high sensitivity to Dasatinib and Rapamycin. Blood. 2018;132(Supplement 1):1557–1557.CrossRef
16.
go back to reference Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019;51(2):296–307.CrossRef Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019;51(2):296–307.CrossRef
17.
go back to reference Liang X, Gu J, Li T, Zhao L, Fu X, Zhang W, et al. PAX5 haploinsufficiency induce cancer cell dormancy in Raji cells. Exp Cell Res. 2018;367:30–6.CrossRef Liang X, Gu J, Li T, Zhao L, Fu X, Zhang W, et al. PAX5 haploinsufficiency induce cancer cell dormancy in Raji cells. Exp Cell Res. 2018;367:30–6.CrossRef
18.
go back to reference Jamrog L, Chemin G, Fregona V, Coster L, Pasquet M, Oudinet C, et al. PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice. Proc Natl Acad Sci USA. 2018;115(41):10357–62.CrossRef Jamrog L, Chemin G, Fregona V, Coster L, Pasquet M, Oudinet C, et al. PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice. Proc Natl Acad Sci USA. 2018;115(41):10357–62.CrossRef
19.
go back to reference Smeenk L, Fischer M, Jurado S, Jaritz M, Azaryan A, Werner B, et al. Molecular role of the PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia. EMBO J. 2017;36(6):718–35.CrossRef Smeenk L, Fischer M, Jurado S, Jaritz M, Azaryan A, Werner B, et al. Molecular role of the PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia. EMBO J. 2017;36(6):718–35.CrossRef
20.
go back to reference Ebinger S, Ozdemir EZ, Ziegenhain C, Tiedt S, Castro Alves C, Grunert M, et al. Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia. Cancer Cell. 2016;30(6):849–62.CrossRef Ebinger S, Ozdemir EZ, Ziegenhain C, Tiedt S, Castro Alves C, Grunert M, et al. Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia. Cancer Cell. 2016;30(6):849–62.CrossRef
Metadata
Title
Functional analysis of a novel fusion protein PAX5-KIDINS220 identified in a pediatric Ph-like ALL patient
Authors
Takuyo Kanayama
Toshihiko Imamura
Azusa Mayumi
Emi Soma
Kenichi Sakamoto
Fumihiko Hayakawa
Akihiko Tanizawa
Nobutaka Kiyokawa
Hajime Hosoi
Publication date
01-11-2020
Publisher
Springer Singapore
Published in
International Journal of Hematology / Issue 5/2020
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-020-02944-4

Other articles of this Issue 5/2020

International Journal of Hematology 5/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine